Effects of Lycium Barbarum Supplements on the Progression of Senile Cataract in Hong Kong Chinese Population

Overview

With the rapid growing aging population, age-related eye diseases including cataract are becoming more prevalent. The demand for cataract surgery and post-surgical care posed enormous financial burdens to the government.

Lycium barbarum contains lutein and zeaxanthin which can filter the phototoxic blue light and neutralize the reactive oxygen species, thus provide a protective effect against cataract formation.

This study aims to determine the effects of Lycium barbarum Supplements on the progression of senile cataract in Hong Kong Chinese elderly.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: April 2012

Detailed Description

Please note that a manuscript for this study is being prepared. Detailed description will be provided after we come up with the final draft.

Interventions

  • Dietary Supplement: Starch
    • 1350mg/day
  • Dietary Supplement: Lycium Barbarum
    • 1350mg/day

Arms, Groups and Cohorts

  • Active Comparator: Placebo
    • Starch
  • Experimental: Lycium Barbarum
    • Lycium Barbarum supplement

Clinical Trial Outcome Measures

Primary Measures

  • Lens Opacity Classification System III (LOCSIII)
    • Time Frame: 3 years

Secondary Measures

  • Visual Acuity
    • Time Frame: 3 years

Participating in This Clinical Trial

Inclusion Criteria

  • Unlikely to have cataract surgery within 3 years
  • Presence of mild to moderate cataract in one or both eyes, graded by Lens Opacities Classification System III (LOCSIII).
  • logMAR acuity equivalent to Snellen acuity of 20/63 or better
  • no previous history and clinical signs of glaucoma by determining intraocular pressure using applanation Tonometry (no more than 22mmHg)
  • no ocular anomalies: amblyopia, binocular anomalies, ocular trauma
  • no history of eye surgery, laser treatment, iritis, retinal crystalline deposits, macular degeneration, or optic nerve diseases
  • no extended use of systemic or ocular corticosteroid drugs
  • no concurrent participation of other systemic or ocular drug intervention study

Exclusion Criteria

  • diabetes mellitus
  • renal failure
  • fat malabsorption syndrome
  • intestinal surgery history
  • chronic diarrhea
  • alcoholism
  • use of anticoagulants
  • regular use of nutritional supplements such as multi-vitamin, mineral and other antioxidant supplements (including Omega-3)

Gender Eligibility: All

Minimum Age: 60 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • The Hong Kong Polytechnic University
  • Collaborator
    • The Hong Kong Jockey Club Charities Trust
  • Provider of Information About this Clinical Study
    • Principal Investigator: Chea-su Kee, Associate Professor – The Hong Kong Polytechnic University
  • Overall Official(s)
    • Chi-wai Do, PhD, Principal Investigator, The Hong Kong Polytechnic University
    • Chea-su Kee, PhD, Principal Investigator, The Hong Kong Polytechnic University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.